[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595840":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":20,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiotherapy plus Anlotinib","EXPERIMENTAL","Radiotherapy plus anlotinib in LA-NSCLC intolerable to cCRT",[13],"Drug: Anlotinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Anlotinib","For patients treated with conventional Intensity-Modulated Radiation Therapy (IMRT), the median prescribed dose was 60 Gy\u002F30 fractions (range: 50.0-70.0 Gy, in 25-35 fractions) (median BED10 72 Gy, range: 60-84 Gy) to the planning target volume (PTV). As for patients with IMRT-based simultaneously integrated boost (SIB), the median prescribed dose was 59.92 Gy\u002F28 fractions (range: 50.0-70.0 Gy, in 25-33 fractions) (median BED10 72.74 Gy, range: 60-84 Gy) to the planning gross tumor volume (PGTV), and 50.4 Gy\u002F28 fractions (range: 45-59.4 Gy, in 25-33 fractions) (median BED10 59.47 Gy, range: 53.1-70.1 Gy) to the PTV. It should be noted that the PTV in the SIB group contains the PGTV.\n\nAnlotinib was administered orally concurrently with the first day of radiotherapy, at a dose of 12 mg for a maximum of three cycles. Each cycle was defined as 2 weeks on-treatment followed by 1 week off-treatment. If intolerance occurs, the dose may be reduced to 8-10 mg\u002Fday or stopped.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"jianyang wang","National Cancer Center","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"jianyang wang, MD","CONTACT","+86-13810095191","pkucell@163.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Department of Radiation Oncology,Cancer Institute and Hospital,Chinese","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":23,"role":29,"phone":49,"phoneExt":20,"email":31},"+8613810095191",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","JIANYANG WANG","Principal Investigator","100595840",false,"NCT07037680","Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT","Efficiency and Safety of Radiotherapy Combined With Anlotinib in Locally Advanced Non-small Cell Lung Cancer Patients Intolerable to Concurrent Chemoradiotherapy: A Phase II Single-arm Trial","Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK\u002FROS1-mutated locally advanced unresectable NSCLC were screened.\n\nInclusion Criteria:\n\n1. ≥18 years old with no restrictions on sex;\n2. Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;\n3. Eastern cooperative oncology group (ECOG) score ≤2 was required;\n4. Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;\n5. .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk;\n6. No symptoms of hemoptysis;\n7. Adequate hepatic and renal functions with a negative urine protein;\n8. Expected survival of more than 6 months.\n\nExclusion Criteria:\n\n1. currently receiving treatment for malignancies at other sites, except for curable non-melanoma skin cancer and cervical carcinoma in situ;\n2. previous malignancy within five years;\n3. thoracic radiotherapy history, hemoptysis, myocardial infarction or cerebrovascular accident within three months;\n4. uncontrolled or active pulmonary inflammation;\n5. participated in other clinical trials;\n6. Pregnant women.","ALL","18 Years",{"count":63,"type":64},44,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.",[70,71,72],"Locally Advanced Non-Small Cell Lung Cancer","Thoracic Radiotherapy","Safety",[74,75,76,77,17],"thoracic radiotherapy","non-small cell lung carcinoma","locally advanced","safety","2025-07-03",{"date":80,"type":81},"2025-07-09","ACTUAL",{"date":83,"type":81},"2024-01-01",{"date":85,"type":64},"2026-06-30",{"name":52,"class":6},1]